<div id="readability-page-1"><p>Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $15.49 and last traded at $15.63, with a volume of 79087 shares trading hands. The stock had previously closed at $15.74.</p><div><p><span></span><span>Get <strong>Janux Therapeutics</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><p>A number of analysts have recently issued reports on the company. Barclays boosted their target price on Janux Therapeutics from $47.00 to $48.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, November 7th. HC Wainwright decreased their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, December 2nd. Cantor Fitzgerald dropped their price objective on shares of Janux Therapeutics from $200.00 to $150.00 and set an &#34;overweight&#34; rating for the company in a research report on Tuesday, December 2nd. UBS Group  reissued a &#34;buy&#34; rating and issued a $57.00 target price on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Finally, Guggenheim assumed coverage on shares of Janux Therapeutics in a research report on Wednesday, September 3rd. They set a &#34;buy&#34; rating and a $72.00 price target for the company. One research analyst  has rated the stock with a Strong Buy rating, twelve have issued  a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $62.67.</p><p><b>Read Our Latest Stock Analysis on JANX</b></p><h2>Janux Therapeutics Stock Down 1.4%</h2><p>The business's 50 day moving average price is $26.47 and its 200-day moving average price is $25.07. The company has a market cap of $933.17 million, a PE ratio of -9.25 and a beta of 2.82. </p><p>Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.21. The firm had revenue of $10.00 million during the quarter, compared to analysts' expectations of $3.07 million.  Equities analysts expect that  Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year. </p><h2>Insider Activity</h2><p>In other news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $32.98, for a total transaction of $109,922.34. Following the sale, the insider directly owned 84,974 shares of the company's stock, valued at approximately $2,802,442.52. The trade was a 3.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Insiders sold 23,331 shares of company stock worth $710,862 over the last 90 days. 29.40% of the stock is currently owned by insiders. </p><h2>Institutional Investors Weigh In On Janux Therapeutics</h2><p>Hedge funds have recently bought and sold shares of the business. Alyeska Investment Group L.P. increased its holdings in  Janux Therapeutics by 64.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 424,845 shares of the company's stock worth $10,383,000 after purchasing an additional 166,167 shares during the last quarter.  Verition Fund Management LLC grew its position in shares of  Janux Therapeutics by 240.3% during the third quarter. Verition Fund Management LLC now owns 40,731 shares of the company's stock worth $995,000 after buying an additional 28,761 shares in the last quarter.  Jain Global LLC bought a new stake in shares of  Janux Therapeutics in the third quarter worth $241,000.  Orbimed Advisors LLC raised its holdings in  Janux Therapeutics by 45.9% in the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company's stock valued at $43,163,000 after acquiring an additional 555,800 shares in the last quarter.  Finally, ADAR1 Capital Management LLC raised its holdings in  Janux Therapeutics by 7.4% in the third quarter. ADAR1 Capital Management LLC now owns 351,032 shares of the company's stock valued at $8,579,000 after acquiring an additional 24,044 shares in the last quarter. Institutional investors and hedge funds own  75.39% of the company's stock. </p><h2>Janux Therapeutics Company Profile</h2> (Get Free Report)<p>Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Janux Therapeutics</li><li>What Makes a Stock a Good Dividend Stock?</li><li>Why AutoZone’s Stock Drop Could Be a Golden Buying Opportunity</li><li>Canada Bond Market Holiday: How to Invest and Trade </li><li>Ollie’s Bargain Outlet Hits Rock-Bottom in Q4: Buy the Dip?</li><li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation </li><li>Insiders Are Selling These 3 Stocks—Here’s Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Janux Therapeutics Right Now?</h2><p>Before you consider Janux Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.</p><p>While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

JANX

<p>Janux Therapeutics (NASDAQ:JANX) hit a new 52-week low at $15.49. Analysts have mixed price targets, with Barclays at $48, HC Wainwright at $45, Cantor Fitzgerald at $150, UBS at $57, and Guggenheim at $72. The company reported better-than-expected earnings and revenue for the last quarter. Insider Andrew Hollman Meyer sold shares recently. Institutional investors have increased their holdings. Janux develops immunotherapies for cancer treatment.</p>

Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week Low - What's Next?